Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK and PD of HRS-8797 in Healthy Subjects
NCT07698756Phase 1Not yet recruiting
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Jul 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-8797 in atopic dermatitis (AD) (2 arms), sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoint: Incidence of adverse events (AE) and serious adverse events (SAE) at Day 21. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
HRS-8797
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT07698756.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07698756.